ArticleBMC health services research2015
Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures.
Article in BMC health services research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Pooled it
- Indirect Cost Analysis and Evaluation of Factors Affecting Indirect Costs in Patients Hospitalized with Acute Coronary Syndrome in Inpatient Wards of a Training and Research Hospital.Healthcare (Basel, Switzerland) · 2026Article
- A systematic review on indirect costs related to loss of productivity after stroke.Health economics review · 2026Review
- Economic burden of malaria on developing countries: A mini review.Parasite epidemiology and control · 2025Review
- Medicaid Expansion Among Nonelderly Adults and Cardiovascular Disease: Efficiency Vs. Equity.The Milbank quarterly · 2025Article
- A cost-effectiveness evaluation of a high-sensitivity troponin I guided voluntary cardiovascular risk assessment program for asymptomatic women in Croatia.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- The Impact of Cardiovascular Disease on Economic Loss.Arquivos brasileiros de cardiologia · 2024Article
- Article
- Setting Goals to Reduce Cardiovascular Risk: A Retrospective Chart Review of a Pharmacist-Led Initiative in the Workplace.International journal of environmental research and public health · 2023Article
- Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk-Enhancing Factor in the Pooled Cohort Equation: A Cost-Effectiveness Analysis Study.Journal of the American Heart Association · 2022Article
- The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States.Journal of managed care & specialty pharmacy · 2022Article
- Estimating the cost-effectiveness of screening a general population for cardiovascular risk with high-sensitivity troponin-I.European heart journal. Quality of care & clinical outcomes · 2022Article
- Not Quite Out of the Woods: Overall Health and Chronic Disease Risk Factors among Maine Logging Workers.Journal of occupational and environmental medicine · 2022Article
- Average lost work productivity due to non-fatal injuries by type in the USA.Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention · 2021Article
- Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling.BMJ open · 2020Article
- The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.Journal of managed care & specialty pharmacy · 2020Article
- Cost-Effectiveness Of A Workplace Ban On Sugar-Sweetened Beverage Sales: A Microsimulation Model.Health affairs (Project Hope) · 2020Article
- Effectiveness of Metoprolol in Improving Cardiac and Motor Functions in Patients with Chronic Heart Failure: A Prospective Study.Drug design, development and therapy · 2020Article
- Population Health Impact and Cost-Effectiveness of Community-Supported Agriculture Among Low-Income US Adults: A Microsimulation Analysis.American journal of public health · 2020Article
- Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015-2017 Years.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe high acute costs of cardiovascular disease and acute cardiovascular events are well established, particularly in terms of direct medical costs. The costs associated with lost work productivity have been described in a broad sense, but little is known about workplace absenteeism or short term disability costs among high cardiovascular risk patients. The objective of this study was to quantify workplace absenteeism (WA) and short-term disability (STD) hours and costs associated with cardiovascular events and related clinical procedures (CVERP) in United States employees with high cardiovascular risk.
methodsMedical, WA and/or STD data from the Truven Health MarketScan® Research Databases were used to select full-time employees aged 18-64 with hyperlipidemia during 2002-2011. Two cohorts (with and without CVERP) were created and screened for medical, drug, WA, and STD eligibility. The CVERP cohort was matched with a non-CVERP cohort using propensity score matching. Work loss hours and indirect costs were calculated for patients with and without CVERP and by CVERP type. Wages were based on the 2013 age-, gender-, and geographic region-adjusted wage rate from the United States Bureau of Labor Statistics.
resultsA total of 5,808 WA-eligible, 21,006 STD-eligible, and 3,362 combined WA and STD eligible patients with CVERP were well matched to patients without CVERP, creating three cohorts of patients with CVERP and three cohorts of patients without CVERP. Demographics were similar across cohorts (mean age 52.2-53.1 years, male 81.3-86.8%). During the first month of follow-up, patients with CVERP had more WA/STD-related hours lost compared with patients without CVERP (WA-eligible: 23.4 more hours, STD-eligible: 51.7 more hours, WA and STD-eligible: 56.3 more hours) (p < 0.001). Corresponding costs were $683, $895, and $1,119 higher, respectively (p < 0.001). Differences narrowed with longer follow-up. In the first month and year of follow-up, patients with coronary artery bypass graft experienced the highest WA/STD-related hours lost and costs compared with patients with other CVERP.
conclusionsCVERP were associated with substantial work loss and indirect costs. Prevention or reduction of CVERP could result in WA and STD-related cost savings for employers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.